MK-8189

Add links
Source: Wikipedia, the free encyclopedia.
MK-8189
Legal status
Legal status
  • Investigational
Identifiers
  • 2-Methyl-6-[[(1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl]methoxy]-N-[(5-methyl-1,3,4-thiadiazol-2-yl)methyl]pyrimidin-4-amine
JSmol)
SMILES
  • CC1=CN=C(C=C1)[C@H]2C[C@@H]2COC3=NC(=NC(=C3)NCC4=NN=C(S4)C)C
  • InChI=1S/C19H22N6OS/c1-11-4-5-16(20-8-11)15-6-14(15)10-26-18-7-17(22-12(2)23-18)21-9-19-25-24-13(3)27-19/h4-5,7-8,14-15H,6,9-10H2,1-3H3,(H,21,22,23)/t14-,15+/m1/s1
  • Key:WQKPZDLZRFTMTI-CABCVRRESA-N

MK-8189 is a selective

phosphodiesterase 10A inhibitor being developed for schizophrenia. It is developed by Merck in collaboration with Royalty Pharma.[1][2][3][4]

See also

References

  1. S2CID 248410630
    .
  2. S2CID 248410556
    .
  3. S2CID 255567942
    .
  4. S2CID 257614478
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=MK-8189&oldid=1269821281"